Monitoring Agency Report for the quarter ended 31st March, 2025
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Epigral Limited has submitted the quarterly Monitoring Agency Report from CARE Ratings for its Qualified Institutions Placement (QIP) of Rs. 333.05 crore conducted in October 2024. The QIP proceeds were earmarked for four purposes: repayment of borrowings (Rs. 250 crore), capital expenditure on fixed assets (Rs. 30 crore), general corporate purposes (Rs. 44.72 crore), and issue expenses (Rs. 8.33 crore). As of the start of Q4FY25, Rs. 292.72 crore had been utilized, and during the quarter, the remaining Rs. 40.33 crore was fully deployed. The Monitoring Agency confirmed there is no deviation from the stated objects and no major changes from earlier reports.
This is a routine regulatory filing confirming that Epigral has fully utilized its QIP proceeds as disclosed. Shareholders can take comfort that there are no deviations or misuse of funds, though the filing itself is unlikely to move the stock price.